Hospital leaders are organizing a lobbying effort to delay or reverse nearly $1 trillion in Medicaid funding cuts over the next decade that were included in Trump's tax cut bill. The industry is exploring strategies to mitigate the damage to their operations and funding.

• Congress passed a law cutting nearly $1 trillion from Medicaid over 10 years as part of the Trump tax cut bill
• Hospital leaders are actively building plans to delay, roll back, or reduce the impact of these cuts
• The hospital industry is mobilizing its lobbying resources in Washington to fight the spending reductions

TrumpRx, a new public-private program launched by the Trump administration in partnership with Pfizer, aims to offer direct-to-consumer drug sales at significantly reduced prices. While it seeks to provide discounts on medications, experts suggest it closely resembles existing DTC models like Cost Plus Drugs and may not substantially impact the majority of patients who rely on insurance for prescriptions.

• TrumpRx is a new public-private drug pricing program launched by the Trump administration with Pfizer offering direct-to-consumer sales at reduced prices.
• Experts say it closely resembles existing DTC models like Mark Cuban's Cost Plus Drugs rather than being a novel approach.
• Since most patients rely on insurance rather than paying cash for prescriptions, the program likely won't have a major impact on the majority of drug purchasers.